- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05536752
Étude de phase II QA102 chez des sujets atteints de DMLA sèche (AMEND)
Une étude dose-réponse de phase 2, à double insu, randomisée, contrôlée par placebo, évaluant l'innocuité et l'efficacité de QA102 chez des sujets atteints de dégénérescence maculaire liée à l'âge (DMLA) sèche
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85021
- Associated Retina Consultants
-
-
California
-
Mountain View, California, États-Unis, 94040
- Northern California Retina Vitreous Associates Medical Group
-
Pasadena, California, États-Unis, 91107
- California Eye Specialists Medical Group
-
Redlands, California, États-Unis, 91107
- California Eye Specialists Medical Group
-
-
Colorado
-
Colorado Springs, Colorado, États-Unis, 80909
- Retina Consultants of Southern Colorado, P.C.
-
-
Florida
-
Deerfield Beach, Florida, États-Unis, 33064
- Advanced Research
-
Fort Myers, Florida, États-Unis, 33912
- National Ophthalmic Research Institute
-
Miami, Florida, États-Unis, 33143
- MedEye Associates
-
Pensacola, Florida, États-Unis, 32503
- Retina Specialty Institute
-
Pinellas Park, Florida, États-Unis, 33782
- Eye Associates of Pinellas
-
Sarasota, Florida, États-Unis, 34239
- Sarasota Retina Institute
-
Winter Haven, Florida, États-Unis, 33880
- Vitreous and Retina Consultants
-
-
Georgia
-
Marietta, Georgia, États-Unis, 30060
- Marietta Eye Clinic
-
-
Illinois
-
Oak Forest, Illinois, États-Unis, 60452
- University Retina and Macula Associates
-
-
Louisiana
-
West Monroe, Louisiana, États-Unis, 71291
- Northeast Louisiana dba Haik Humble Eye Center
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21209
- The Retina Care Center
-
Hagerstown, Maryland, États-Unis, 21740
- Cumberland Valley Retina Consultants
-
Hagerstown, Maryland, États-Unis, 21740
- Mid Atlantic Retina Specialists
-
-
Massachusetts
-
Worcester, Massachusetts, États-Unis, 01605
- Vitreo-Retinal Associates, P.C.
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63144
- Retina Research Institute
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45202
- Velocity Clinical Research
-
-
Oregon
-
Eugene, Oregon, États-Unis, 97401
- Verum Research, LLC
-
-
Pennsylvania
-
Erie, Pennsylvania, États-Unis, 16507
- Erie Retina Research
-
-
Texas
-
Abilene, Texas, États-Unis, 79606
- Retina Research Institute of Texas
-
Austin, Texas, États-Unis, 78705
- Austin Research Center for Retina
-
Dallas, Texas, États-Unis, 75243
- AXIS Clinicals LLC / Retina of North Texas
-
Plano, Texas, États-Unis, 75075
- Texas Retina Associates - Plano
-
San Antonio, Texas, États-Unis, 78215
- San Antonio Eye Center
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84107
- Rocky Mountain Retina Consultants
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
- Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
- Subject must be age ≥50 years at the time of informed consent.
- Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
- Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
- Subject must be willing and able to comply with study procedures and examinations.
Specific to the Study Eye:
-
Subject must have one of the following:
- extensive intermediate-size drusen, or at least 1 large drusen, or
- GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
-
Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).
Specific to Fellow Eye:
- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.
Specific to Both Eyes:
- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.
Key Exclusion Criteria:
- Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
- Subject has ever received gene therapy (for any condition).
- Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
- Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
- Subject had major surgery within 30 days prior to Screening.
Specific to Study Eye:
- Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
- Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
- Subject has endophthalmitis.
- Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
- Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
- Subject has aphakia or absence of the posterior capsule.
- Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)
Specific to Fellow Eye:
Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.
Specific to Either Eye:
- Subject had intraocular surgery with lens replacement within 3 months of Screening.
- Subject has any ophthalmic condition that could require surgery during the study period.
- Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: QA102 200mg group
Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months |
Capsules |
|
Expérimental: QA102 400mg group
Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months |
Capsules |
|
Comparateur placebo: Placebo group
Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months |
Capsules |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change From Baseline in Soft Drusen Volume (mm3)
Délai: Month 12
|
Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set |
Month 12
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean Rate of GA Growth
Délai: Month 12
|
Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline |
Month 12
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- QA102-CS201
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .